ICIs that block PD-1, PD-L1, and CTLA-4, such as nivolumab, pembrolizumab, and ipilimumab, have shown clinical benefit in metastatic ccRCC by reactivating T cells and partially reversing immune suppression [10,11]. This evidence concerns the gene CTLA4 and nonpapillary renal cell carcinoma.